Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

342
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
342
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

544
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
544
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

731
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
731
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

366
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
366
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

791
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
791
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

676
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
676

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn's disease pathogenesis.

Nature genetics·2026
Same author

Cell-type-resolved genetic variation shapes inflammatory bowel disease risk.

Nature·2026
Same author

Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial.

Journal of Crohn's & colitis·2026
Same author

Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn's disease.

Journal of Crohn's & colitis·2026
Same author

Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.

Journal of Crohn's & colitis·2026
Same author

Corticosteroid Use in Childhood-Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006-2022).

United European gastroenterology journal·2026

Related Experiment Video

Updated: Dec 14, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K

IBD considerations in spondyloarthritis.

Caroline Di Jiang1, Tim Raine2

  • 1Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK.

Therapeutic Advances in Musculoskeletal Disease
|July 23, 2020
PubMed
Summary

Spondyloarthritis (SpA) patients often experience gastrointestinal inflammation. Early diagnosis and tailored management of inflammatory bowel diseases (IBD) are crucial for these individuals.

Keywords:
crohn’s diseaseinflammatory bowel diseasespondyloarthritisulcerative colitis

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

234
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

5.3K

Related Experiment Videos

Last Updated: Dec 14, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

234
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

5.3K

Area of Science:

  • Rheumatology
  • Gastroenterology
  • Immunology

Background:

  • Spondyloarthritis (SpA) is a group of autoimmune disorders characterized by joint inflammation.
  • SpA shares pathophysiological links with immune-mediated inflammatory diseases like inflammatory bowel diseases (IBD).
  • Gastrointestinal inflammation is a common comorbidity in patients with SpA.

Purpose of the Study:

  • To review the shared epidemiology and pathophysiology of SpA and IBD.
  • To discuss diagnostic and management strategies for gastrointestinal pathology in SpA patients.
  • To differentiate non-specific gastrointestinal inflammation from specific IBD diagnoses (Crohn's disease, ulcerative colitis).

Main Methods:

  • Literature review focusing on shared aspects of SpA and IBD.
  • Discussion of diagnostic workup for suspected IBD in rheumatology settings.
  • Analysis of treatment implications for comorbid SpA and IBD.

Main Results:

  • Individuals with SpA frequently exhibit gastrointestinal inflammation.
  • Distinguishing non-specific inflammation from IBD is critical for appropriate care.
  • IBD diagnosis impacts treatment selection, dosing, monitoring, and safety in SpA patients.

Conclusions:

  • Awareness of gastrointestinal manifestations in SpA is essential for rheumatologists.
  • A systematic approach to diagnosing IBD in SpA patients improves outcomes.
  • Personalized treatment strategies are necessary for managing comorbid SpA and IBD.